Tuesday, 29 September 2019
Meeting category
Date(s)
29 Sep 2019
Location
Salvador,
Brazil
Organizer
Salvador HIV Clinical Forum 2019
Related Enduring Materials
Enduring Materials
Session 1: Integrase Inhibitor Characteristics -
Session Chairs
Resistance to INSTIs and How Resistance Impacts Treatment Choices
Pharmacology Considerations When Choosing INSTIs
Toxicity Considerations When Choosing INSTIs
Session 2: Optimal Use of INSTIs in the Clinic -
Session Chairs
Role of INSTIs in HIV Prevention
Experience with Dolutegravir in First-Line in Brazil
Switching to INSTI-Based Treatment in Viral Suppressed Patients
Clinical Case
Session 3: INSTI Use in Special Populations -
Session Chairs
Estevão Nunes, MD
Fundação Oswaldo Cruz, Brazil
INSTIs Use in Women at Child-Bearing Age: NTD Risks
INSTIs Use in Pediatrics
Treatment Options for HIV-TB Co-Infection
Session 4: HIV Therapy in the Near Future -
Session Chairs
Ian Frank, MD
University of Pennsylvania, United States
Time to Change the Paradigm: Two vs. Three Drugs
Long Acting ARV: Drugs and Delivery Systems
General
Welcome
We would like to thank you for joining us at this year’s Salvador HIV Clinical Forum 2019 in Brazil.
We have experienced excellent discussions and lectures during this meeting!
On behalf of the Program Chairs we would like to thank our conference supporter ViiV Healthcare for their unrestricted generous support and all of the endorsers!
We would like to encourage you and your colleagues to plan submission of your upcoming research results to the next edition of the meeting.
The Program Chairs
Program Chairs
Jonathan Schapiro, MD
National Hemophilia Center Sheba Medical Center, Israel
Charles Boucher MD, PhD
Medical Center, The Netherlands
Mauro Schechter MD, PhD
Federal University of Rio de Janeiro, Brazil
Local Chair
Carlos Brites MD
Universidade Federal da Bahia, Brazil
General Information
Meeting Objectives
With the HIV Clinical Forum program we aim to:
- Build a community of healthcare professionals devoted to providing optimal clinical care for their patients
- Create a platform for interactive information exchange on novel treatment options
- Translate the latest research achievements into clinical guidance for the optimal management of HIV-positive individuals
- Build a community of healthcare professionals devoted to providing optimal clinical care for their patients
- Create a platform for interactive information exchange on novel treatment options
- Translate the latest research achievements into clinical guidance for the optimal management of HIV-positive individuals
Learning Objectives
After participating in the HIV Clinical Forum, participants will be able to:
- Describe the basic science of integrase inhibition
- Summarize how and when to apply Integrase Inhibitors in daily clinical practice
- Describe the resistance characteristics of integrase inhibitors
- Discuss the challenges of treating special populations (such as co-infected patients, women, elderly, etc.) and how to address them
- Summarize the treatment results of ongoing studies and clinical case studies
- Identify future treatment opportunities involving integrase inhibitors
- Describe the basic science of integrase inhibition
- Summarize how and when to apply Integrase Inhibitors in daily clinical practice
- Describe the resistance characteristics of integrase inhibitors
- Discuss the challenges of treating special populations (such as co-infected patients, women, elderly, etc.) and how to address them
- Summarize the treatment results of ongoing studies and clinical case studies
- Identify future treatment opportunities involving integrase inhibitors
Committees
Program Chairs
Jonathan Schapiro, MD
National Hemophilia Center Sheba Medical Center, Israel
Charles Boucher, MD, PhD
Erasmus Medical Center, the Netherlands
Mauro Schechter MD, PhD
Federal University of Rio de Janeiro, Brazil
Local Chair
Carlos Brites, MD
Universidade Federal da Bahia, Brazil
The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop, identify interesting topics and candidate speakers, and review all submitted abstracts.
Support
Support
Meeting Partners
